Vir Biotechnology Stock Alpha and Beta Analysis
| VIR Stock | USD 6.95 0.21 3.12% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Vir Biotechnology. It also helps investors analyze the systematic and unsystematic risks associated with investing in Vir Biotechnology over a specified time horizon. Remember, high Vir Biotechnology's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Vir Biotechnology's market risk premium analysis include:
Beta 2.54 | Alpha (0.55) | Risk 4.31 | Sharpe Ratio (0.06) | Expected Return (0.25) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Vir |
Vir Biotechnology Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Vir Biotechnology market risk premium is the additional return an investor will receive from holding Vir Biotechnology long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Vir Biotechnology. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Vir Biotechnology's performance over market.| α | -0.55 | β | 2.54 |
Vir Biotechnology expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Vir Biotechnology's Buy-and-hold return. Our buy-and-hold chart shows how Vir Biotechnology performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Vir Biotechnology Market Price Analysis
Market price analysis indicators help investors to evaluate how Vir Biotechnology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Vir Biotechnology shares will generate the highest return on investment. By understating and applying Vir Biotechnology stock market price indicators, traders can identify Vir Biotechnology position entry and exit signals to maximize returns.
Vir Biotechnology Return and Market Media
The median price of Vir Biotechnology for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 7.76 with a coefficient of variation of 9.38. The daily time series for the period is distributed with a sample standard deviation of 0.75, arithmetic mean of 8.0, and mean deviation of 0.58. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 18000 shares by Sato Vicki L of Vir Biotechnology at 24.662 subject to Rule 16b-3 | 09/17/2024 |
2 | Disposition of 10028 shares by George Scangos of Vir Biotechnology at 10.0456 subject to Rule 16b-3 | 09/20/2024 |
3 | Insider Trading | 10/01/2024 |
4 | Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLDs The Liver Meeting 2024 | 10/15/2024 |
5 | Acquisition by George Scangos of 598270 shares of Vir Biotechnology subject to Rule 16b-3 | 10/23/2024 |
6 | Vir Biotechnology Q3 2024 Earnings Preview | 10/30/2024 |
7 | Disposition of 1403 shares by De Verneuil Vanina of Vir Biotechnology at 7.20 subject to Rule 16b-3 | 11/01/2024 |
8 | Analysts Have Lowered Expectations For Vir Biotechnology, Inc. After Its Latest Results | 11/04/2024 |
9 | Disposition of 2347 shares by De Verneuil Vanina of Vir Biotechnology at 9.4696 subject to Rule 16b-3 | 11/05/2024 |
10 | Disposition of 4397 shares by De Verneuil Vanina of Vir Biotechnology at 10.11 subject to Rule 16b-3 | 11/07/2024 |
11 | Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency | 11/18/2024 |
About Vir Biotechnology Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Vir or other stocks. Alpha measures the amount that position in Vir Biotechnology has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.44 | 0.41 | Days Of Inventory On Hand | 42.86 | 38.1 |
Vir Biotechnology Upcoming Company Events
As portrayed in its financial statements, the presentation of Vir Biotechnology's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Vir Biotechnology's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Vir Biotechnology's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Vir Biotechnology. Please utilize our Beneish M Score to check the likelihood of Vir Biotechnology's management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Vir Biotechnology
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Vir Stock Analysis
When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.